Tango Therapeutics Achieves 92% Response Rate in Hard-to-Treat Pancreatic Cancer
Tango drug combo shows 92% response in advanced pancreatic cancer, with strong early results and good safety in trials.
/ 3 items
#TNGX↓
2026 Could Be Huge: Mizuho Predicts Major Stock Surge for Tango Therapeutics on Phase 1 Data
Mizuho starts coverage on Tango Therapeutics with an Outperform rating and $19 price target, highlighting strong potential for lead drug vopimetostat in tough cancers like pancreatic and lung.
Stifel Begins Coverage of Tango Therapeutics with Bullish Outlook
Stifel initiates coverage of Tango Therapeutics with a Buy rating and $15 target, citing strong potential for its PRMT5 inhibitor vopimetostat and forecasting $1.2B in peak global revenue by 2035.